Paige.AI
built the first AI pathology product cleared by the FDA (Paige Prostate), and in 2025 received FDA Breakthrough Device designation for Paige PanCancer Detect, an AI tool that flags suspicious cancer foci across multiple tissues and organs on a single AI-first digital-pathology platform.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI pathology interpretation (computational pathology) | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.